nyuuzyou/wikis huggingface dataset:
Ferric carboxymaltose (Injectafer)

==General information==
Class/mechanism: Colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.Ferric carboxymaltose (Injectafer) package insert Ferric carboxymaltose (Injectafer) package insert (locally hosted backup)Injectafer manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Ferric carboxymaltose (Injectafer) patient drug information
==History of changes in FDA indication==
*2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
*2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have non-dialysis-dependent chronic kidney disease.
==Also known as==
*Brand name: Injectafer
==References==
Category:Drugs
Category:Intravenous medications
Category:Hematology medications
Category:Iron replacement
Category:FDA approved in 2013
Ferric gluconate (Ferrlecit)

==General information==
Class/mechanism: Iron, which is needed for various biologic processes, including synthesis of hemoglobin and multiple enzymatic processes.Ferric gluconate (Ferrlecit) package insert Ferric gluconate (Ferrlecit) package insert (locally hosted backup)Ferrlecit manufacturer's website
Route: IV
Extravasation: no information
*1 mL of Ferrlecit provides 12.5 mg of elemental iron
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Ferric gluconate (Ferrlecit) patient drug information (UpToDate)Ferric gluconate (Ferrlecit) patient drug information (UpToDate)
==History of changes in FDA indication==
*1999-02-18: Approved for treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoetin therapy.
==Also known as==
*Generic name: sodium ferric gluconate complex in sucrose injection
*Brand name: Ferrlecit
==References==
Category:Drugs
Category:Intravenous medications
Category:Hematology medications
Category:Iron replacement
Category:FDA approved in 1999
Ferrous sulfate (Feosol)

==General information==
Class/mechanism: Iron, which is needed for various biologic processes, including synthesis of hemoglobin and multiple enzymatic processes.Feosol manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Ferrous sulfate patient drug information (UpToDate)Ferrous sulfate patient drug information (UpToDate)
==Also known as==
*Brand names: Fe Tabs, Feosol, Fer Iron, Fer-Gen-Sol, Fer-in-Sol, Fer-Iron, Feratab, FeroSul, Ferra-TD, Ferra T.D. Caps, Ferro-Bob
==References==
Category:Drugs
Category:Oral medications
Category:Hematology medications
Category:Iron replacement
Ferumoxytol (Feraheme)

==General information==
Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.Ferumoxytol (Feraheme) package insert Ferumoxytol (Feraheme) package insert (locally hosted backup)Feraheme manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Ferumoxytol (Feraheme) patient drug informationFerumoxytol (Feraheme) patient drug information
*Ferumoxytol (Feraheme) patient drug information (UpToDate)Ferumoxytol (Feraheme) patient drug information (UpToDate)
==History of changes in FDA indication==
*2009-06-30: Initial approval for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).
==Also known as==
*Brand name: Feraheme
==References==
Category:Drugs
Category:Intravenous medications
Category:Hematology medications
Category:Iron replacement
Category:FDA approved in 2009
Figitumumab (CP-751,871)

==Mechanism of action==
From the NCI Drug Dictionary: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth.
==Also known as==
*Code name: CP-751,871
Category:Drugs
Category:Intravenous medications
Category:Anti-IGF-1R antibodies
Category:Halted drugs
Category:Stub
Filanesib (ARRY-520)

==Mechanism of action==
From the NCI Drug Dictionary: A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing.
==Also known as==
*Code name: ARRY-520
Category:Drugs
Category:Intravenous medications
Category:KSP inhibitors
Category:Investigational drugs
Category:Stub
Filgrastim-aafi (Nivestym)

==General information==
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation.
Route: SC
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
Note that colony stimulating factors may be used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; but they are not thought to have inherent anti-cancer activity.
==History of changes in FDA indication==
*2018-07-20: Approved as a biosimilar to US-licensed Neupogen for the five indications for which US-licensed Neupogen is approved:
**"Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever"
**"Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)"
**"Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)"
**"Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis"
**"Reduce the incidence and duration of sequelae of severe neutropenia (e.g.,fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia"
==History of changes in EMA indication==
*2010-06-07: Initial authorization as Nivestim
==Also known as==
*Brand name: Nivestim, Nivestym
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Granulocyte colony-stimulating factors
Category:EMA approved in 2010
Category:FDA approved in 2018
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Filgrastim-ayow (Releuko)

==General information==
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation.
Route: SC
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
Note that colony stimulating factors may be used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; but they are not thought to have inherent anti-cancer activity.
==History of changes in FDA indication==
*2022-05-22: Approved as a biosimilar to US-licensed Neupogen.
==Also known as==
*Brand names: Releuko
Category:Drugs
Category:Subcutaneous medications
Category:Granulocyte colony-stimulating factors
Category:FDA approved in 2022
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Filgrastim-sndz (Zarxio)

==General information==
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. The formulation of Filgrastim-sndz (Zarxio) differs from that of Filgrastim (Neupogen) in one inactive component.Filgrastim-sndz (Zarxio) package insert Filgrastim-sndz (Zarxio) package insert (locally hosted backup)Zarxio manufacturer's website
Route: SC
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
Note that colony stimulating factors may be used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; but they are not thought to have inherent anti-cancer activity.
==Patient drug information==
*Filgrastim-sndz (Zarxio) package insert
==History of changes in FDA indication==
*2015-03-06: FDA Approved as a biosimilar to US-licensed Neupogen for the five indications for which US-licensed Neupogen is approved:
**"Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever"
**"Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)"
**"Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)"
**"Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis"
**"Reduce the incidence and duration of sequelae of severe neutropenia (e.g.,fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia"
==History of changes in EMA indication==
*2009-02-06: Initial authorization as Zarzio
==Also known as==
*Brand names: Zarxio, Zarzio
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Granulocyte colony-stimulating factors
Category:EMA approved in 2009
Category:FDA approved in 2015
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Finasteride (Proscar)

==General information==
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.Finasteride (Proscar) package insertFinasteride (Proscar) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Patient drug information==
*Finasteride (Proscar) patient drug information (UpToDate)Finasteride (Proscar) patient drug information (UpToDate)
==History of changes in FDA indication==
No antineoplastic label, at this time.
*1992-06-19: Initial approval
==Also known as==
*Brand name: Proscar
==References==
Category:Drugs
Category:Oral medications
Category:Antiandrogens
Category:5 alpha-reductase inhibitors
Category:FDA approved in 1992
Finotonlimab (SCT-I10A)

==Mechanism of action==
From NCI Drug Dictionary: A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SCT-I10A targets, binds to, and inhibits PD-1 and its downstream signaling pathways. This may restore immune functions through the activation of T cells and T-cell-mediated immune responses against tumor cells.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Head and neck cancer===
#SCT-I10A-B301: Shi Y, Guo W, Wang W, Wu Y, Fang M, Huang X, Han P, Zhang Q, Dong P, Zhou X, Peng H, Hu C, Chen X, Zhang S, Chang Z, Li X, Ding Y, Qu S, Jing S, Zhang S, Gui L, Sun Y, Wang L, Liu Y, Wu H, Li G, Fu Z, Shi J, Jiang H, Bai Y, Cui J, Zheng Y, Cui W, Jia X, Zhai L, Cai Q, Xiong D, Wu Y, Cao J, Wu R, Hu G, Peng L, Xie L, Gai W, Wang Y, Su Y. Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial. Nat Med. 2024 Sep;30(9):2568-2575. Epub 2024 Jun 28. link to original article EuroPMC NCT04146402
==Also known as==
*Code name: SCT-I10A
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-1 antibodies
Category:Head and neck cancer medications (investigational)
Category:Investigational drugs
Fitusiran (ALN-AT3SC)

==Mechanism of action==
siRNA therapeutic, targets antithrombin
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Inherited coagulopathy===
#ATLAS-A/B: Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You CW, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang CY, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023 May;10(5):e322-e332. Epub 2023 Mar 29. link to original article EuroPMC NCT03417245
Category:Drugs
Category:Subcutaneous medications
Category:Inherited coagulopathy medications (investigational)
Category:Investigational drugs
Category:Stub
Floxuridine (FUDR)

==General information==
Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. When given by rapid intraarterial injection, it is rapidly catabolized in vivo to fluorouracil (5-FU), which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP). When FUDR is given by continuous intraarterial infusion, direct anabolism to FUDR-monophosphate is enhanced, which increases the inhibition of DNA.Floxuridine (FUDR) package insertFloxuridine (FUDR) package insert (locally hosted backup)
Route: IA (intraarterial)
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Patient drug information==
*Floxuridine (FUDR) patient drug information (Chemocare)Floxuridine (FUDR) patient drug information (Chemocare)
*Floxuridine (FUDR) patient drug information (UpToDate)Floxuridine (FUDR) patient drug information (UpToDate)
==Disease for which it is used==
*Colorectal cancer
==History of changes in FDA indication==
* 1970-12-18: Initial FDA approval for the palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Patients with known disease extending beyond an area capable of infusion via a single artery should, except in unusual circumstances, be considered for systemic therapy with other chemotherapeutic agents. (No supporting studies are cited)
==Also known as==
*Code name: WR-138720
*Generic names: floxuridin, fluorodeoxyuridine, fluorouridine deoxyribose
*Brand name: FUDR
==References==
Category:Drugs
Category:Irritant
Category:Intra-arterial medications
Category:Fluoropyrimidines
Category:Colorectal cancer medications
Category:FDA approved in 1970
Category:Discontinued drugs
Flumatinib (Xinfu)

==General information==
From the NCI Drug Dictionary: The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. 
==Diseases for which it is used==
*Chronic myeloid leukemia
# FESTnd: Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Sun A, Hu Y, Jin J, Jiang H, Zhang X, Li Y, Liu L, Zhang W, Liu X, Gu J, Qiao J, Ouyang G, Liu X, Luo J, Jiang M, Xie X, Li J, Zhao C, Zhang M, Yang T, Wang J. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clin Cancer Res. 2021 Jan 1;27(1):70-77. Epub 2020 Sep 14. link to original article EuroPMC NCT02204644
==History of changes in NMPA approval==
*2019-11-25: Initial approval for the treatment of adult patients with Philadelphia chromosome positive chronic myelogenous leukemia (Ph＋CML) in the chronic phase.
==Also known as==
*Code name: HH-GV-678
*Generic name: flumatinib mesylate
*Brand name: Xinfu
Category:Drugs
Category:Oral medications
Category:Bcr-Abl inhibitors
Category:KIT inhibitors
Category:PDGFR inhibitors
Category:Chronic myeloid leukemia medications
Category:NMPA approved in 2019
Fluoxymesterone (Halotestin)

==Mechanism of action==
Androgen and anabolic steroid
==Diseases for which it was used==
*Breast cancer
==History of changes in FDA indication==
*1956-10-15: Initial FDA approval
==Also known as==
*Brand names: Halotestin, Ultandren
Category:Drugs
Category:Oral medications
Category:Anabolic steroids
Category:Breast cancer medications (historic)
Category:FDA approved in 1956
Category:Discontinued drugs
Flutamide (Eulexin)

==General information==
Class/mechanism: Antiandrogen; non-steroidal. Inhibits androgen uptake and/or inhibits nuclear binding of androgen in target tissues.Flutamide (Eulexin) package insertFlutamide (Eulexin) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Flutamide (Eulexin) patient drug information (Chemocare)Flutamide (Eulexin) patient drug information (Chemocare)
*Flutamide (Eulexin) patient drug information (UpToDate)Flutamide (Eulexin) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1989-01-27: Initial FDA approval for use in combination with LHRH agonistic analogs (such as leuprolide acetate) for the treatment of metastatic prostatic carcinoma (stage D2). To achieve the benefit of the adjunctive therapy with EUFLEX, treatment must be started simultaneously using both drugs. EUFLEX Tablets are also indicated as an adjunctive therapy to orchiectomy, in order to achieve complete androgen blockade. (Based on SWOG-8494)
* 1989-01-27: Also approved in combination with LHRH agonists are also indicated prior to and during definitive external beam radiotherapy for patients with bulky locally advanced Stage B2 and Stage C prostatic carcinoma. (Based on Pilepich et al. 1995)
==History of changes in EMA indication==
*1982-03-24: EURD
==Also known as==
*Brand names: Cytomid, Euflex, Eulexin, Flutamid, Flutatec, Lutamide, Proscan, Tamid
==References==
Category:Drugs
Category:Oral medications
Category:First-generation nonsteroidal antiandrogens
Category:Prostate cancer medications
Category:FDA approved in 1989
Category:EMA approved in 1982